Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | RNA recognition motif domain containing protein | 0.0063 | 1 | 1 |
Trypanosoma brucei | DNA polymerase eta, putative | 0.0019 | 0.1197 | 1 |
Mycobacterium ulcerans | DNA polymerase IV | 0.0019 | 0.1197 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0019 | 0.1197 | 1 |
Trypanosoma cruzi | DNA polymerase eta, putative | 0.0019 | 0.1197 | 0.5 |
Mycobacterium tuberculosis | Possible DNA-damage-inducible protein P DinP (DNA polymerase V) (pol IV 2) (DNA nucleotidyltransferase (DNA-directed)) | 0.0019 | 0.1197 | 0.5 |
Loa Loa (eye worm) | RNA binding protein | 0.0063 | 1 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0019 | 0.1197 | 1 |
Loa Loa (eye worm) | TAR-binding protein | 0.0063 | 1 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0063 | 1 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0019 | 0.1197 | 1 |
Trypanosoma cruzi | DNA polymerase kappa, putative | 0.0019 | 0.1197 | 0.5 |
Trichomonas vaginalis | DNA polymerase IV / kappa, putative | 0.0019 | 0.1197 | 0.5 |
Leishmania major | DNA polymerase kappa, putative,DNA polymerase IV, putative | 0.0019 | 0.1197 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0063 | 1 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0063 | 1 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0063 | 1 | 1 |
Trypanosoma cruzi | DNA polymerase kappa, putative | 0.0019 | 0.1197 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0063 | 1 | 1 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0063 | 1 | 1 |
Echinococcus granulosus | tar DNA binding protein | 0.0063 | 1 | 1 |
Echinococcus multilocularis | tar DNA binding protein | 0.0063 | 1 | 1 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.0019 | 0.1197 | 1 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.0019 | 0.1197 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0019 | 0.1197 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0019 | 0.1197 | 1 |
Trypanosoma brucei | unspecified product | 0.0019 | 0.1197 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0019 | 0.1197 | 1 |
Mycobacterium tuberculosis | Conserved hypothetical protein | 0.0019 | 0.1197 | 0.5 |
Trichomonas vaginalis | DNA polymerase eta, putative | 0.0019 | 0.1197 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0019 | 0.1197 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0019 | 0.1197 | 1 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.0019 | 0.1197 | 1 |
Entamoeba histolytica | deoxycytidyl transferase, putative | 0.0019 | 0.1197 | 0.5 |
Giardia lamblia | DINP protein human, muc B family | 0.0019 | 0.1197 | 0.5 |
Trypanosoma cruzi | DNA polymerase kappa, putative | 0.0019 | 0.1197 | 0.5 |
Leishmania major | DNA polymerase kappa, putative | 0.0019 | 0.1197 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0019 | 0.1197 | 1 |
Trypanosoma cruzi | DNA polymerase kappa, putative | 0.0019 | 0.1197 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0019 | 0.1197 | 1 |
Leishmania major | DNA polymerase eta, putative | 0.0019 | 0.1197 | 0.5 |
Mycobacterium ulcerans | DNA polymerase IV | 0.0019 | 0.1197 | 0.5 |
Brugia malayi | TAR-binding protein | 0.0063 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
EC50 (functional) | = 0.11 uM | Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D10 expressing yeast DHODH infected in O-positive erythrocytes assessed as reduction in parasitemia after 72 hrs by spectrofluorometry in presence of PG | ChEMBL. | 22435599 |
EC50 (ADMET) | > 21.5 uM | Cytotoxicity against human Raji cells after 72 hrs by luminescence analysis | ChEMBL. | 22435599 |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 | 22435599 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.